New company established to operate NSW’s world-leading viral vector facility at Westmead Health Precinct

[tta_listen_btn listen_text=”Click here to have this article read aloud” pause_text=”Pause” resume_text=”Resume” replay_text=”Replay”]

The NSW Government has announced the establishment of a new company to operate the world-leading viral vector manufacturing facility based at Westmead Health Precinct, which will produce groundbreaking and life-saving therapies.

Viral vectors are a key component of many cell and gene therapies, and vaccines, which are increasingly being used to treat cancer, genetic diseases and infections.

Viral vector technology uses viruses that are harmless to humans to carry genetic therapies to the target organs and systems that cause significant human diseases.

This is cutting-edge, world class work happening right here in western Sydney.

Treasurer, Daniel Mookhey

Establishing a commercial company with an agile, responsive operating model will provide a strong base for the sustainable, long-term success of the Viral Vector Manufacturing facility.

Stage 1 of the facility is operational for use in gene therapy research with the first clinical trial anticipated to commence in 2025 using vectors from the facility.

The Stage 2 facility is currently under construction and once completed will provide NSW with a commercial-scale viral vector manufacturing facility capable of meeting the growing demand for viral vectors.

“The facility is an important part of the Westmead Health and Innovation Precinct here in western Sydney, ” Member for Parramatta, Donna Davis, said.

Completion of construction works is expected by the end of 2024, with Good Manufacturing Practice certification to follow soon after.

The company is to be registered as Viral Vector Manufacturing Facility Pty Ltd.

It will manufacture the vectors and supply them to specialised healthcare staff, who will deliver the therapies to patients.

Overall, the NSW Government has committed $134.5 million to establish the Facility and to manufacture viral vector products for research and clinical trials.

Investing in health precincts like this one is an important part of making sure that research can thrive and is integrated in the wider health ecosystem.

Minister for Medical Research, David Harris